Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

If your constipation lasts for more than three days, speak with your doctor about options to help. You might need to add a ...

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.

The following is a summary of “Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist Use ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney ...